By admin 
The internal crisis within the American Diabetes Association (ADA) has intensified significantly, with the organization’s executive leadership taking the extraordinary step of blocking editors at its flagship medical journal from publishing an editorial and a series of first-person accounts. These suppressed documents detail a high-profile confrontation that occurred during the group’s annual meeting last month, an event that has already sent shockwaves through the global endocrinology and diabetes research communities. The move to spike the content in Diabetes Care, one of the most prestigious journals in the field of metabolic research, represents a rare and controversial intervention by a non-profit’s administrative arm into the editorial independence of its scientific publishing house.
The controversy traces back nearly five weeks to the ADA’s 84th Scientific Sessions held in New Orleans. During this premier gathering of thousands of clinicians, researchers, and industry stakeholders, five prominent diabetes specialists were abruptly escorted out of the convention center by security personnel. Their offense was the distribution of reprints of an editorial previously published in Diabetes Care titled "Misguided Brushes of a Pen Continue to Dismantle." That original piece expressed profound concern over significant cuts to federal research funding and policy shifts under the Trump administration that critics argue have undermined the National Institutes of Health (NIH) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
The ejection of these specialists—highly respected figures within the academic community—was captured in real-time on social media, leading to immediate national attention and a swift backlash from the association’s membership. In the days following the New Orleans incident, the ADA issued a public apology, characterizing the evictions as an overreaction and promising a "formal, independent review" of the security protocols and the decision-making process that led to the specialists being removed. However, the goodwill generated by that apology has largely evaporated following the recent decision to suppress a follow-up editorial intended to address the fallout of the event.
According to sources close to the journal’s editorial board, Diabetes Care had prepared a comprehensive package for its upcoming issue. This included an official editorial reflecting on the importance of academic freedom and the right of members to engage in advocacy, as well as first-person accounts from the five specialists who were removed. These accounts reportedly detailed the "humiliating" experience of being treated like trespassers at a professional conference they had attended for decades. The ADA leadership, however, intervened to "delay" the publication, citing the ongoing nature of their internal review. Critics and several members of the editorial board view this not as a delay, but as a "spiking" of content that is critical of the current administration’s handling of the crisis.
In response to this perceived censorship, the suppressed editorial and the personal testimonies have been uploaded to Zenodo, an open-access repository operated by CERN. This move to bypass official channels highlights the deepening rift between the ADA’s executive suite and its scientific membership. On this open-access platform, the diabetes specialists who were ejected detail their treatment in stark terms, describing a climate of intimidation. They argue that the ADA’s leadership prioritized political optics over the protection of its members’ voices.
The content now circulating on Zenodo includes contributions from prominent ADA members, including past presidents and a high-ranking official who resigned in protest shortly after the New Orleans confrontation. These voices express a shared dismay over how the events were handled, both in the moment and in the weeks of administrative silence that followed. A central point of contention is the ADA’s apparent discomfort with views that oppose the policies of the Trump administration. The original editorial that sparked the ejections was a critique of federal budget priorities, and many within the ADA believe the organization is fearful of losing its standing with federal regulators or risking its non-profit status by appearing too "partisan."
However, the authors of the suppressed pieces argue that advocating for research funding is not a partisan issue but a foundational mission of the ADA. They contend that by silencing those who speak out against federal cuts, the ADA is failing in its duty to the millions of Americans living with diabetes who rely on the fruits of NIH-funded research. The disagreement has also extended to the "formal review" promised by the ADA. While the organization maintains that the review is being conducted with integrity, dissenting members claim there is a lack of transparency regarding who is conducting the investigation and whether the final report will ever be made public in its entirety.
The implications of this editorial interference are profound for the field of scientific publishing. Editorial independence is a cornerstone of medical journals; it ensures that the evidence and opinions presented are not filtered by the financial or political interests of the parent organization. By blocking the publication of a peer-reviewed editorial, the ADA leadership has called into question the autonomy of Diabetes Care. This has led to calls for the journal’s editorial board to assert its independence or for members to reconsider their contributions to the publication.
The "New Orleans Five," as they have become known in some academic circles, are not fringe activists but established researchers whose work has been instrumental in shaping modern diabetes care. Their removal from the convention center was seen by many as a symbolic act of "cleansing" the meeting of dissent. The subsequent suppression of their written accounts has only served to solidify the narrative that the ADA is facing a leadership crisis. The specialists argue that the organization has become increasingly corporate in its structure, distancing itself from the grassroots needs of the scientific community and the patients they serve.
Logical analysis of the ADA’s current position suggests a difficult path forward. If the organization continues to block the publication of the editorial after the "review" is completed, it risks a mass exodus of high-profile members and a permanent stain on its reputation as a scientific authority. Conversely, if it allows the publication, it must contend with a public record of its own leadership’s failures. The situation is further complicated by the broader political landscape, where scientific organizations are increasingly caught in the crossfire of national policy debates regarding healthcare spending, drug pricing, and the role of federal agencies.
The ADA’s financial health and influence are also at stake. As the world’s leading voluntary health organization in the field of diabetes, it manages a massive budget funded by donations, corporate sponsorships, and membership dues. If the academic community perceives the ADA as an organization that prioritizes administrative control over scientific discourse, it may see a decline in participation at its annual meetings—events that generate significant revenue. Furthermore, the ADA’s "Standards of Medical Care in Diabetes," which are published annually in Diabetes Care, are the gold standard for clinical practice. Any loss of credibility for the journal could inadvertently cast a shadow over these vital guidelines.
Expert perspectives on the matter are largely critical of the ADA’s executive actions. "A scientific society that is afraid of the opinions of its own most distinguished members is a society in deep trouble," noted one former NIH director who requested anonymity. "The journal is supposed to be a forum for debate. When you close that forum because the debate is uncomfortable for the board of directors, you have ceased to be a scientific society and have become a trade association or a lobbying group."
As the controversy continues to unfold, the eyes of the medical community remain fixed on the ADA’s next steps. The disagreement over the conduct of the internal review suggests that the "formal report" may not provide the closure the leadership hopes for. Instead, the release of the suppressed documents on Zenodo has ensured that the voices of the New Orleans Five and their supporters will be heard, regardless of the ADA’s official stance. This incident serves as a stark reminder of the tensions that can arise when the rigorous, often critical nature of scientific inquiry clashes with the cautious, brand-protective instincts of large non-profit institutions.
In the long term, this episode may prompt a broader discussion within the scientific community about the governance of professional societies. There are growing calls for clearer "firewalls" between the executive leadership of such organizations and the editorial boards of their journals. For now, the American Diabetes Association remains an organization divided, struggling to reconcile its history of advocacy with a current leadership style that many of its members find increasingly unrecognizable and restrictive. The "fresh turn" in this turmoil is likely not the last, as the push for transparency and academic freedom continues to challenge the ADA’s status quo.
